

## PRESS RELEASE

Stockholm, March 23, 2004

## ELEKTA RECEIVES ACHIEVEMENT AWARD FOR CORPORATE EXCELLENCE

Elekta in the U.S. has received the prestigious "Achievement Award 2004 for corporate excellence". The award is presented by the Swedish Trade Council, the Consulate General of Sweden and the Swedish-American Chamber of Commerce in San Francisco and is awarded to Swedish companies with affiliations in the U.S. The award recognizes the excellent contribution Elekta has made to Swedish-American trade in its marketing and sales efforts.

The common element for all Achievement Award recipients is success. The nominated companies were judged by the following criteria:

- Overall performance, competitiveness and capabilities
- Commercial success and development
- Achieved market position

## Reasons for success in the US

Elekta entered the US market already in 1983 with an office in Atlanta, where Elekta's US headquarter is located today. The US is an important market for Elekta both in size, 40 percent of total revenues, and in clinical and technology demand.

Elekta installed its first Leksell Gamma Knife<sup>®</sup> in the US at the University of Pittsburgh in 1987, the same year as the first unit was installed at the Karolinska Hospital in Sweden.

The introduction of Leksell Gamma Knife<sup>®</sup> in the US has been a great success. Today more or less all neurosurgical departments at major hospitals in the US perform neurosurgery using Leksell Gamma Knife<sup>®</sup>. It has become the gold standard of care for non-invasive treatment of brain disorders including functional diseases i.e. epilepsy and Parkinson's disease.

By the end of December 2003, there were 193 Leksell Gamma Knife<sup>®</sup> units installed world-wide of which 86 units are in the US.

Elekta is also a leading supplier in the U.S. and in the world of systems for radiation therapy of cancer.

When Elekta acquired Philips radiotherapy division in 1997 the market share in the US for systems for radiation of cancer was less than 10 percent. Today Elekta's market share is close to 25 percent. Elekta is today the second largest supplier in the world of systems for radiation treatment of cancer.



This is a result of a strong research and technical development program, started when Elekta took over from Philips, which today has brought Elekta to a position of technological leadership in the radiation therapy market. As an example, Elekta is today the only company with systems in clinical operation that are capable of image-guided radiation therapy - integrating equipment for high resolution 3D x-ray images onto a linear accelerator. The US is taking the lead in this development and it is therefore important for Elekta to be a strong player in the US marketplace.

\* \* \* \* \* \* \* \* \* \* \*

## For further information, please contact:

International: Peter Ejemyr, Group VP Corporate Communications, Elekta AB (publ), Phone: +46 733 611 000, e-mail: peter.ejemyr@elekta.com

United States: Lars Jonsteg, VP Investor Relations North America, Elekta, USA Phone: +1 770-670-2419, e-mail: lars.jonsteg@elekta.com

Elekta is a world-leading supplier of advanced and innovative radiation oncology and neurosurgery solutions and services for precise treatment of cancer and brain disorders. Elekta's solutions are clinically effective, cost efficient and gentle to the patient.

For additional information about Elekta, please visit www.elekta.com